All News
Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk
Janet Pope Janetbirdope ( View Tweet)
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Olga Petryna DrPetryna ( View Tweet)
FAST trial: allopurinol vs febuxostat on safety
(for gout pts on allopurinol, with ≥1 CV RF, TTT dosing)
febuxostat non-inferior for CV events
Well, that's a relief.
gout flare similar, good follow-up, colchicine did not influence
out in Lancet today?
#ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9
David Liew drdavidliew ( View Tweet)
Results of the FAST trial presented at #ACR20
- Safety study required by the EMA
- Febuxostat non-inferior to allopurinol for any outcomes
- Long-term use of febuxostat is not associated with an increased risk of death
Published in @TheLancet today https://t.co/EvJGPpDCR8
Links:
NatRevRheumatol NatRevRheumatol ( View Tweet)
Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest
Richard Conway RichardPAConway ( View Tweet)
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2
Dr. John Cush RheumNow ( View Tweet)
Read my #ACR20 article on diet as a mechanism to control gout @rheumnow https://t.co/nEWJqt8eXx
Richard Conway RichardPAConway ( View Tweet)
Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr McCormick presents on causal association between hyperuricaemia and diabetes. Insulin resistance causal for high urate. Target insulin resistance to prevent gout. @rheumnow #ACR20 Abstr#1472 https://t.co/OSr3ktIXSS
Richard Conway RichardPAConway ( View Tweet)
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Mrinalini Dey DrMiniDey ( View Tweet)
Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV
Richard Conway RichardPAConway ( View Tweet)
Study incl 1243 #SLE patients finds excess risk of #cardiovascular events is underestimated by CVD prediction tools- the underestimation may be increased in those with more severe disease activity.
Abs#1286 #ACR20 @RheumNow
https://t.co/6FZvxE02CF
Mrinalini Dey DrMiniDey ( View Tweet)
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crystal Arthritis and Gout Highlights at ACR: Dr. Nicola Dalbeth
Gout specialist Dr. Nicola Dalbeth from Aukland, New Zealand provides a preview perspective on crystal arthritis and gout studies and sessions at #ACR20.
https://t.co/QfVSpeVXlf https://t.co/cBwKF5P5eb
Links:
Dr. John Cush RheumNow ( View Tweet)
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers https://t.co/fRB2zuKl5J #gout #uricosuric a novel uricosuric agent
Peter Nash drpnash ( View Tweet)
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W
Richard Conway RichardPAConway ( View Tweet)
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
Richard Conway RichardPAConway ( View Tweet)
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
Richard Conway RichardPAConway ( View Tweet)
